Technical Solvency Looking Forward

Quote

anonymous

Guest
I truly am starting to wonder if ES is a viable long-term entity. The cash burn rate is pretty significant, less than two years worth of cash on hand. Cutting some jobs will definitely help, but given the evolving market environment I’m wondering if this company will be ever be profitable. Seems like we’re on thin ice, definitely feels a lot different than three years ago to me.
 






anonymous said:
I truly am starting to wonder if ES is a viable long-term entity. The cash burn rate is pretty significant, less than two years worth of cash on hand. Cutting some jobs will definitely help, but given the evolving market environment I’m wondering if this company will be ever be profitable. Seems like we’re on thin ice, definitely feels a lot different than three years ago to me.
Click to expand...
This was a huge reality check for many people that the answer to your question looks like a hard no. Many who were on the fence about looking for new jobs got plenty of motivation to do so after yesterday. Multiple reorgs and 3 lay offs in less than a year doesn't bode well for the future
 






Did I hear correctly that clinical programs have been put on hold. Where does that leave 2.0? Maybe company feels that 1.5 is good enough and a more sensitive/specific product is not needed.
 












Top Bottom
Back
Quote